- Adaptive resistance to lorlatinib via EGFR signaling in ALK-rearranged lung cancer
Yuki Katayama et al, 2023, npj Precision Oncology CrossRef - Structure-Based Design of a Potent and Selective Covalent Inhibitor for SRC Kinase That Targets a P-Loop Cysteine
Guangyan Du et al, 2020, Journal of Medicinal Chemistry CrossRef - Polyclonal on- and off-target resistance mutations in an EML4-ALK positive non-small cell lung cancer patient under ALK inhibition
Marcel Kemper et al, 2021, Oncotarget CrossRef - ALK-Positive Non-Small Cell Lung Cancer; Potential Combination Drug Treatments
Shrestha Nensi et al, 2021, Current Cancer Drug Targets CrossRef - Experimental Determination of Cancer Drug Targets with Independent Mechanisms of Resistance
John C. Ashton et al, 2022, Current Cancer Drug Targets CrossRef - Concurrent inhibition of ALK and SRC kinases disrupts the ALK lung tumor cell proteome
Alberto Diaz-Jimenez et al, 2024, Drug Resistance Updates CrossRef - Establishment of an acquired lorlatinib-resistant cell line of non-small cell lung cancer and its mediated resistance mechanism
Bo Xie et al, 2022, Clinical and Translational Oncology CrossRef - EML4‐ALK biology and drug resistance in non‐small cell lung cancer: a new phase of discoveries
Mariam Elshatlawy et al, 2023, Molecular Oncology CrossRef - Safety and Activity of the Combination of Ceritinib and Dasatinib in Osteosarcoma
Olaf Beck et al, 2020, Cancers CrossRef - EML4-ALK induces cellular senescence in mortal normal human cells and promotes anchorage-independent growth in hTERT-transduced normal human cells
Akihiko Miyanaga et al, 2021, BMC Cancer CrossRef - Lorlatinib as a treatment for ALK-positive lung cancer
Keisuke Baba et al, 2022, Future Oncology CrossRef - Anti-diabetic drug metformin inhibits cell proliferation and tumor growth in gallbladder cancer via G0/G1 cell cycle arrest
Takuma Yamashita et al, 2020, Anti-Cancer Drugs CrossRef - Prospective observational study to explore genes and proteins predicting efficacy and safety of brigatinib for ALK-gene rearranged non-small-cell lung cancer: study protocol for ABRAID study (WJOG11919L)
Yuichi Ozawa et al, 2024, Therapeutic Advances in Medical Oncology CrossRef - ALK Inhibitors-Induced M Phase Delay Contributes to the Suppression of Cell Proliferation
Sirajam Munira et al, 2020, Cancers CrossRef - Good clinical response to alectinib, a second generation ALK inhibitor, in refractory neuroblastoma
John A. Heath et al, 2018, Pediatric Blood & Cancer CrossRef - The Use of Alectinib in the First-Line Treatment of Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer
Shirish M Gadgeel, 2018, Future Oncology CrossRef - Unraveling the Potential of ALK-Targeted Therapies in Non-Small Cell Lung Cancer: Comprehensive Insights and Future Directions
Hannaneh Parvaresh et al, 2024, Biomedicines CrossRef - GSK3 inhibition circumvents and overcomes acquired lorlatinib resistance in ALK-rearranged non-small-cell lung cancer
Yuki Shimizu et al, 2022, npj Precision Oncology CrossRef - Current Knowledge about Mechanisms of Drug Resistance against ALK Inhibitors in Non-Small Cell Lung Cancer
Elisabeth Smolle et al, 2021, Cancers CrossRef - Rack1 mediates Src binding to drug transporter P-glycoprotein and modulates its activity through regulating Caveolin-1 phosphorylation in breast cancer cells
Yanling Fan et al, 2019, Cell Death & Disease CrossRef - Protein tyrosine kinase inhibitor resistance in malignant tumors: molecular mechanisms and future perspective
Yang Yang et al, 2022, Signal Transduction and Targeted Therapy CrossRef